Prior authorization requirements for Sublocade

Effective February 1, 2019, prior authorization (PA) requirements will change for the injectable/infusible drug Sublocade to be covered by Amerigroup. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

**PA requirements will be added to the following:**
- Sublocade (Buprenorphine) — implant (J0570)
- Sublocade — injectable (Q9991, Q9992)

**To request PA, you may use one of the following methods:**
- **Web:** [https://www.availity.com](https://www.availity.com)
- **Fax:** 1-800-964-3627
- **Phone:** 1-800-454-3730

Not all PA requirements are listed here. PA requirements are available to contracted and noncontracted providers on our provider website ([https://providers.amerigroup.com/TX > Provider Resources & Documents > Quick Tools > Precertification Lookup Tool](https://providers.amerigroup.com/TX)). Providers may also call us at 1-800-454-3730 for PA requirements.